These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22905596)
41. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016 [TBL] [Abstract][Full Text] [Related]
42. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Dahl R; Stender A; Rak S Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194 [TBL] [Abstract][Full Text] [Related]
43. [Immunotherapy for allergic rhinitis induced by Japanese cedar pollens]. Ohashi Y Arerugi; 2008 May; 57(5):519-23. PubMed ID: 18520172 [No Abstract] [Full Text] [Related]
44. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830 [TBL] [Abstract][Full Text] [Related]
45. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. Colás C; Monzón S; Venturini M; Lezaun A J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938 [TBL] [Abstract][Full Text] [Related]
46. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Savolainen J; Jacobsen L; Valovirta E Allergy; 2006 Oct; 61(10):1184-90. PubMed ID: 16942566 [TBL] [Abstract][Full Text] [Related]
47. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Alvarez-Cuesta E; Aragoneses-Gilsanz E; Martín-Garcia C; Berges-Gimeno P; Gonzalez-Mancebo E; Cuesta-Herranz J Clin Exp Allergy; 2005 May; 35(5):572-8. PubMed ID: 15898977 [TBL] [Abstract][Full Text] [Related]
48. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. Matricardi PM; Kuna P; Panetta V; Wahn U; Narkus A J Allergy Clin Immunol; 2011 Oct; 128(4):791-799.e6. PubMed ID: 21620452 [TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland. Brüggenjürgen B; Reinhold T J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271 [TBL] [Abstract][Full Text] [Related]
50. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684 [TBL] [Abstract][Full Text] [Related]
51. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097 [TBL] [Abstract][Full Text] [Related]
52. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Hordijk GJ; Antvelink JB; Luwema RA Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731 [TBL] [Abstract][Full Text] [Related]
53. A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelines. Sola J; Sánchez V; Landeta A; Madariaga B; Martínez A; Álvarez-Cuesta E Immunotherapy; 2015; 7(4):343-52. PubMed ID: 25917626 [TBL] [Abstract][Full Text] [Related]
54. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Worm M Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520 [TBL] [Abstract][Full Text] [Related]
55. Negative clinical results from a randomised, double-blind, placebo-controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose-dependent immunological response. Kleine-Tebbe J; Walmar M; Bitsch-Jensen K; Decot E; Pfaar O; de Rojas DH; Rodriguez F Clin Drug Investig; 2014 Aug; 34(8):577-86. PubMed ID: 24997093 [TBL] [Abstract][Full Text] [Related]
56. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764 [TBL] [Abstract][Full Text] [Related]
57. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126 [TBL] [Abstract][Full Text] [Related]
58. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Panzner P; Petrás M; Sýkora T; Lesná I Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908 [TBL] [Abstract][Full Text] [Related]
59. Dosing and efficacy in specific immunotherapy. Demoly P; Calderon MA Allergy; 2011 Jul; 66 Suppl 95():38-40. PubMed ID: 21668851 [TBL] [Abstract][Full Text] [Related]
60. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]